Orthobiologic Soft Tissue Repair

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface
With the acquisitions of Parcus Medical and Arthrosurface, Anika looks ready to complete a major step in its five-year strategic plan to become a leader in joint preservation and restoration.

Member-Only Content

SUBSCRIBE Login

Embody Gains Additional Funding for ACL Repair

Embody Gains Additional Funding for ACL Repair
Embody is receiving a $2.5 million Phase II research award. Funds will support development and clinical assessment of collagen-based MICROBRACE™ ACL technology for anterior cruciate ligament repair.

Histogenics to Explore Strategic Alternatives for NeoCart Cartilage Treatment

Histogenics plans to evaluate the range of potential strategic alternatives for its NeoCart® cell therapy following FDA's indication that an additional clinical trial would be required before acceptance of a Biologics License Application submission. 

Histogenics’ Top-Line Results From Phase 3 Trial of NeoCart

Histogenics' Phase III clinical trial of NeoCart® tissue engineered implant did not meet the primary endpoint of a statistically significant improvement in pain and function vs. microfracture in a dual threshold responder analysis at one year.

Wright Medical Acquiring Cartiva

Wright Medical is acquiring Cartiva, a manufacturer of the Synthetic Cartilage Implant to treat arthritis in the great toe, for US $435MM. The transaction is expected to close in 4Q18.

Vericel Prices $65MM Public Offering of Stock

Vericel, developer of MACI® autologous cultured chondrocytes for cartilage repair, priced its underwritten public offering of 5MM shares of common stock at $13/share.

Orthobiologics: Conversations with CEOs

At AAOS, we sat down with the CEOs of Bioventus and Histogenics to ask about opportunities that their companies are embracing, as well as the health of the orthobiologics market. Both mentioned advancements in therapies demonstrated through clinical trials and outcomes, and both discussed the importance of keeping younger, active patients healthy and mobile. Here we recap a portion of those conversations.

CartiHeal Raises $18.3 Million

CartiHeal closed a US $18.3MM financing round, supporting the recently-approved IDE clinical trial of the Agili-C™ implant.

Cartiva Secures $8.5MM Funding

Cartiva secured US $8.5MM in a Series E financing. Proceeds will support commercialization of the Synthetic Cartilage Implant for treatment of great toe arthritis.

Histogenics Closes $30.0 Million Private Placement

Histogenics closed its previously-announced US $30.0MM private placement. Funds will support development of NeoCart® novel cartilage repair therapy, including completion of the ongoing Phase III clinical trial.

Histogenics Announces $30.0MM Private Placement

Histogenics seeks to raise ~US $30.0MM in a private placement. Net proceeds will support development of NeoCart® cartilage repair therapy, including completion of an ongoing Phase III clinical trial.

Rotation Medical Completes $12MM Series B Financing

Rotation Medical completed a US $12MM Series B extension financing. Proceeds will support U.S. commercialization of its rotator cuff repair system, comprising a proprietary bioinductive implant and disposable instruments. 

CartiHeal Raises $15 Million

CartiHeal completed a US $15MM financing round. Funds will support ongoing manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C™ cartilage regeneration technology.